Adrenal Gland Disease
5
0
1
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 5 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (5)
The ARISE Trial Compares Whether Giving Routine Steroid Replacement or Using Targeted Blood Tests to Guide Replacement Better Protects Certain Patients From Adrenal Insufficiency After the Removal of a Diseased Adrenal Gland.
Prospective Phenotyping of Autonomous Aldosterone Secretion
Subcutaneous Hydrocortisone Children With Congenital Adrenal Hyperplasia
EUS-guided FNA in the Study of the Adrenal Gland
Lipid-poor Adrenal Masses: Evaluation With Chemical Shift MRI